ID   CP2B6_HUMAN             Reviewed;         491 AA.
AC   P20813; B4DWP3; Q2V565; Q9UK46;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   10-MAY-2017, entry version 187.
DE   RecName: Full=Cytochrome P450 2B6;
DE            EC=1.14.13.-;
DE   AltName: Full=1,4-cineole 2-exo-monooxygenase;
DE   AltName: Full=CYPIIB6;
DE   AltName: Full=Cytochrome P450 IIB1;
GN   Name=CYP2B6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=2573390; DOI=10.1021/bi00444a029;
RA   Yamano S., Nhamburo P.T., Aoyama T., Meyer U.A., Inaba T., Kalow W.,
RA   Gelboin H.V., McBride O.W., Gonzalez F.J.;
RT   "cDNA cloning and sequence and cDNA-directed expression of human P450
RT   IIB1: identification of a normal and two variant cDNAs derived from
RT   the CYP2B locus on chromosome 19 and differential expression of the
RT   IIB mRNAs in human liver.";
RL   Biochemistry 28:7340-7348(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ALA-167; HIS-172
RP   AND ARG-262.
RC   TISSUE=Liver;
RA   Zhuge J., Qian Y., Xie H., Yu Y.;
RT   "Sequence of a new human cytochrome P450-2B6 cDNA.";
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Colon;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-22; SER-26;
RP   GLY-28; SER-29; HIS-172; ARG-262; LYS-289; SER-306; THR-328 AND
RP   CYS-487.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 26-491 (ISOFORM 1).
RX   PubMed=2813061; DOI=10.1093/nar/17.20.8241;
RA   Miles J.S., McLaren A.W., Wolf C.R.;
RT   "Alternative splicing in the human cytochrome P450IIB6 gene generates
RT   a high level of aberrant messages.";
RL   Nucleic Acids Res. 17:8241-8255(1989).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=10768437; DOI=10.1016/S0140-6736(00)99016-0;
RA   Thum T., Borlak J.;
RT   "Gene expression in distinct regions of the heart.";
RL   Lancet 355:979-983(2000).
RN   [8]
RP   CATALYTIC ACTIVITY, FUNCTION AS 1,4-CINEOLE 2-EXO-MONOOXYGENASE, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11695850; DOI=10.1080/00498250110065595;
RA   Miyazawa M., Shindo M., Shimada T.;
RT   "Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-
RT   cineole, a monoterpene cyclic ether, by rat and human liver
RT   microsomes.";
RL   Xenobiotica 31:713-723(2001).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 30-491 OF VARIANT ARG-262 IN
RP   COMPLEX WITH HEME AND SYNTHETIC INHIBITOR, FUNCTION, COFACTOR, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=20061448; DOI=10.1124/mol.109.062570;
RA   Gay S.C., Shah M.B., Talakad J.C., Maekawa K., Roberts A.G.,
RA   Wilderman P.R., Sun L., Yang J.Y., Huelga S.C., Hong W.X., Zhang Q.,
RA   Stout C.D., Halpert J.R.;
RT   "Crystal structure of a cytochrome P450 2B6 genetic variant in complex
RT   with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution.";
RL   Mol. Pharmacol. 77:529-538(2010).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 30-491 OF VARIANT ARG-262 IN
RP   COMPLEX WITH HEME AND SYNTHETIC INHIBITOR, FUNCTION, AND COFACTOR.
RX   PubMed=21875942; DOI=10.1124/mol.111.074427;
RA   Shah M.B., Pascual J., Zhang Q., Stout C.D., Halpert J.R.;
RT   "Structures of cytochrome P450 2B6 bound to 4-benzylpyridine and 4-(4-
RT   nitrobenzyl)pyridine: insight into inhibitor binding and rearrangement
RT   of active site side chains.";
RL   Mol. Pharmacol. 80:1047-1055(2011).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 30-491 IN COMPLEX WITH HEME
RP   AND AMLODIPINE, FUNCTION, AND COFACTOR.
RX   PubMed=22909231; DOI=10.1021/bi300894z;
RA   Shah M.B., Wilderman P.R., Pascual J., Zhang Q., Stout C.D.,
RA   Halpert J.R.;
RT   "Conformational adaptation of human cytochrome P450 2B6 and rabbit
RT   cytochrome P450 2B4 revealed upon binding multiple amlodipine
RT   molecules.";
RL   Biochemistry 51:7225-7238(2012).
RN   [13]
RP   POLYMORPHISM, INVOLVEMENT IN EFAVIRENZ POOR METABOLISM, AND
RP   SUSCEPTIBILITY TO EFAVIRENZ TOXICITY.
RX   PubMed=15622315;
RA   Haas D.W., Ribaudo H.J., Kim R.B., Tierney C., Wilkinson G.R.,
RA   Gulick R.M., Clifford D.B., Hulgan T., Marzolini C., Acosta E.P.;
RT   "Pharmacogenetics of efavirenz and central nervous system side
RT   effects: an Adult AIDS Clinical Trials Group study.";
RL   AIDS 18:2391-2400(2004).
RN   [14]
RP   POLYMORPHISM, INVOLVEMENT IN EFAVIRENZ POOR METABOLISM, AND
RP   SUSCEPTIBILITY TO EFAVIRENZ TOXICITY.
RX   PubMed=20639527; DOI=10.1093/jac/dkq260;
RA   Carr D.F., la Porte C.J., Pirmohamed M., Owen A., Cortes C.P.;
RT   "Haplotype structure of CYP2B6 and association with plasma efavirenz
RT   concentrations in a Chilean HIV cohort.";
RL   J. Antimicrob. Chemother. 65:1889-1893(2010).
RN   [15]
RP   POLYMORPHISM, INVOLVEMENT IN EFAVIRENZ POOR METABOLISM, AND
RP   SUSCEPTIBILITY TO EFAVIRENZ TOXICITY.
RX   PubMed=20860463; DOI=10.2217/pgs.10.94;
RA   Elens L., Vandercam B., Yombi J.C., Lison D., Wallemacq P.,
RA   Haufroid V.;
RT   "Influence of host genetic factors on efavirenz plasma and
RT   intracellular pharmacokinetics in HIV-1-infected patients.";
RL   Pharmacogenomics 11:1223-1234(2010).
RN   [16]
RP   VARIANT HIS-172.
RX   PubMed=11243870; DOI=10.1006/bbrc.2001.4524;
RA   Ariyoshi N., Miyazaki M., Toide K., Sawamura Y.I., Kamataki T.;
RT   "A single nucleotide polymorphism of CYP2b6 found in Japanese enhances
RT   catalytic activity by autoactivation.";
RL   Biochem. Biophys. Res. Commun. 281:1256-1260(2001).
RN   [17]
RP   VARIANTS CYS-22; HIS-172; ARG-259; ARG-262 AND CYS-487.
RX   PubMed=11470993; DOI=10.1097/00008571-200107000-00004;
RA   Lang T., Klein K., Fischer J., Nussler A.K., Neuhaus P., Hofmann U.,
RA   Eichelbaum M., Schwab M., Zanger U.M.;
RT   "Extensive genetic polymorphism in the human CYP2B6 gene with impact
RT   on expression and function in human liver.";
RL   Pharmacogenetics 11:399-415(2001).
RN   [18]
RP   CHARACTERIZATION OF VARIANTS CYS-22; HIS-172; ARG-259; ARG-262 AND
RP   CYS-487.
RX   PubMed=12642465; DOI=10.1124/dmd.31.4.398;
RA   Jinno H., Tanaka-Kagawa T., Ohno A., Makino Y., Matsushima E.,
RA   Hanioka N., Ando M.;
RT   "Functional characterization of cytochrome P450 2B6 allelic
RT   variants.";
RL   Drug Metab. Dispos. 31:398-403(2003).
RN   [19]
RP   VARIANTS CYS-22; ALA-167; HIS-172 AND CYS-487.
RX   PubMed=12721789; DOI=10.1007/s10038-003-0021-7;
RA   Saito S., Iida A., Sekine A., Kawauchi S., Higuchi S., Ogawa C.,
RA   Nakamura Y.;
RT   "Catalog of 680 variations among eight cytochrome p450 (CYP) genes,
RT   nine esterase genes, and two other genes in the Japanese population.";
RL   J. Hum. Genet. 48:249-270(2003).
RN   [20]
RP   VARIANTS CYS-22; GLU-139; HIS-172 AND CYS-487.
RX   PubMed=14551287; DOI=10.1124/jpet.103.054866;
RA   Lamba V., Lamba J., Yasuda K., Strom S., Davila J., Hancock M.L.,
RA   Fackenthal J.D., Rogan P.K., Ring B., Wrighton S.A., Schuetz E.G.;
RT   "Hepatic CYP2B6 expression: gender and ethnic differences and
RT   relationship to CYP2B6 genotype and CAR (constitutive androstane
RT   receptor) expression.";
RL   J. Pharmacol. Exp. Ther. 307:906-922(2003).
RN   [21]
RP   VARIANTS LEU-21; VAL-46; GLU-99; GLU-139; GLN-140 AND ASN-391.
RX   PubMed=15190123; DOI=10.1124/jpet.104.068973;
RA   Lang T., Klein K., Richter T., Zibat A., Kerb R., Eichelbaum M.,
RA   Schwab M., Zanger U.M.;
RT   "Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians:
RT   demonstration of phenotypic null alleles.";
RL   J. Pharmacol. Exp. Ther. 311:34-43(2004).
RN   [22]
RP   VARIANTS CYS-22; HIS-172; ARG-262; THR-328 AND CYS-487.
RX   PubMed=15469410; DOI=10.1517/14622416.5.7.895;
RA   Solus J.F., Arietta B.J., Harris J.R., Sexton D.P., Steward J.Q.,
RA   McMunn C., Ihrie P., Mehall J.M., Edwards T.L., Dawson E.P.;
RT   "Genetic variation in eleven phase I drug metabolism genes in an
RT   ethnically diverse population.";
RL   Pharmacogenomics 5:895-931(2004).
CC   -!- FUNCTION: Cytochromes P450 are a group of heme-thiolate
CC       monooxygenases. In liver microsomes, this enzyme is involved in an
CC       NADPH-dependent electron transport pathway. It oxidizes a variety
CC       of structurally unrelated compounds, including steroids, fatty
CC       acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
CC       {ECO:0000269|PubMed:11695850, ECO:0000269|PubMed:20061448,
CC       ECO:0000269|PubMed:21875942, ECO:0000269|PubMed:22909231}.
CC   -!- CATALYTIC ACTIVITY: 1,4-cineole + NADPH + O(2) = 2-exo-hydroxy-
CC       1,4-cineole + NADP(+) + H(2)O. {ECO:0000269|PubMed:11695850}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000269|PubMed:20061448,
CC         ECO:0000269|PubMed:21875942, ECO:0000269|PubMed:22909231};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=360 uM for 1,4-cineole {ECO:0000269|PubMed:11695850};
CC         Vmax=3.4 nmol/min/nmol enzyme toward 2-exo-hydroxy-1,4-cineole
CC         {ECO:0000269|PubMed:11695850};
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Peripheral
CC       membrane protein. Microsome membrane; Peripheral membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P20813-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P20813-2; Sequence=VSP_055571, VSP_055572;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in liver, lung and heart right
CC       ventricle. {ECO:0000269|PubMed:10768437}.
CC   -!- INDUCTION: By phenobarbital.
CC   -!- PTM: Phosphorylation is accompanied by a decrease in enzyme
CC       activity. {ECO:0000250}.
CC   -!- POLYMORPHISM: Genetic variations in CYP2B6 are responsible for
CC       poor metabolism of efavirenz and, therefore, susceptibility to
CC       efavirenz toxicity in the central nervous system [MIM:614546].
CC       Efavirenz is a non-nucleoside reverse transcriptase inhibitor
CC       frequently prescribed with 2 nucleoside reverse transcriptase
CC       inhibitors as initial therapy for human immunodeficiency virus
CC       (HIV) infection. Up to half of patients treated with efavirenz,
CC       experience side effects in the central nervous system, including
CC       dizziness, insomnia, impaired concentration, somnolence, and
CC       abnormal dreams. Severe depression, aggressive behavior, and
CC       paranoid or manic reactions may also occur, depending on efavirenz
CC       concentration in the plasma.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Cytochrome P450 Allele Nomenclature Committee;
CC       Note=CYP2B6 alleles;
CC       URL="http://www.cypalleles.ki.se/cyp2b6.htm";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cyp2b6/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M29874; AAA52144.1; -; mRNA.
DR   EMBL; AF182277; AAF13602.1; -; mRNA.
DR   EMBL; AK301620; BAG63105.1; -; mRNA.
DR   EMBL; DQ298753; ABB84469.1; -; Genomic_DNA.
DR   EMBL; AC023172; AAF32444.1; -; Genomic_DNA.
DR   EMBL; AC011541; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X13494; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS12570.1; -. [P20813-1]
DR   PIR; A32969; A32969.
DR   RefSeq; NP_000758.1; NM_000767.4. [P20813-1]
DR   RefSeq; XP_011524852.1; XM_011526550.2. [P20813-2]
DR   UniGene; Hs.1360; -.
DR   PDB; 3IBD; X-ray; 2.00 A; A=30-491.
DR   PDB; 3QOA; X-ray; 2.10 A; A=27-491.
DR   PDB; 3QU8; X-ray; 2.80 A; A/B/C/D/E/F=27-491.
DR   PDB; 3UA5; X-ray; 2.80 A; A/B=27-491.
DR   PDB; 4I91; X-ray; 2.00 A; A=27-491.
DR   PDB; 4RQL; X-ray; 2.10 A; A/B=27-491.
DR   PDB; 4RRT; X-ray; 2.20 A; A/B=27-491.
DR   PDB; 4ZV8; X-ray; 2.24 A; A=30-491.
DR   PDBsum; 3IBD; -.
DR   PDBsum; 3QOA; -.
DR   PDBsum; 3QU8; -.
DR   PDBsum; 3UA5; -.
DR   PDBsum; 4I91; -.
DR   PDBsum; 4RQL; -.
DR   PDBsum; 4RRT; -.
DR   PDBsum; 4ZV8; -.
DR   ProteinModelPortal; P20813; -.
DR   SMR; P20813; -.
DR   BioGrid; 107933; 4.
DR   STRING; 9606.ENSP00000324648; -.
DR   BindingDB; P20813; -.
DR   ChEMBL; CHEMBL4729; -.
DR   DrugBank; DB08369; 1-(biphenyl-4-ylmethyl)-1H-imidazole.
DR   DrugBank; DB02974; 4-(4-Chlorophenyl)Imidazole.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00381; Amlodipine.
DR   DrugBank; DB00701; Amprenavir.
DR   DrugBank; DB01435; Antipyrine.
DR   DrugBank; DB06413; Armodafinil.
DR   DrugBank; DB06697; Artemether.
DR   DrugBank; DB01076; Atorvastatin.
DR   DrugBank; DB00972; Azelastine.
DR   DrugBank; DB04975; Banoxantrone.
DR   DrugBank; DB00865; Benzphetamine.
DR   DrugBank; DB06770; Benzyl alcohol.
DR   DrugBank; DB04794; Bifonazole.
DR   DrugBank; DB00835; Brompheniramine.
DR   DrugBank; DB01156; Bupropion.
DR   DrugBank; DB00564; Carbamazepine.
DR   DrugBank; DB00748; Carbinoxamine.
DR   DrugBank; DB00439; Cerivastatin.
DR   DrugBank; DB00169; Cholecalciferol.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB00604; Cisapride.
DR   DrugBank; DB00515; Cisplatin.
DR   DrugBank; DB00215; Citalopram.
DR   DrugBank; DB00349; Clobazam.
DR   DrugBank; DB00636; Clofibrate.
DR   DrugBank; DB00758; Clopidogrel.
DR   DrugBank; DB01559; Clotiazepam.
DR   DrugBank; DB00257; Clotrimazole.
DR   DrugBank; DB01394; Colchicine.
DR   DrugBank; DB04664; Cyclohexyl-pentyl-maltoside.
DR   DrugBank; DB00531; Cyclophosphamide.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB01234; Dexamethasone.
DR   DrugBank; DB00514; Dextromethorphan.
DR   DrugBank; DB00829; Diazepam.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB01075; Diphenhydramine.
DR   DrugBank; DB01184; Domperidone.
DR   DrugBank; DB00997; Doxorubicin.
DR   DrugBank; DB00625; Efavirenz.
DR   DrugBank; DB08899; Enzalutamide.
DR   DrugBank; DB00751; Epinastine.
DR   DrugBank; DB00199; Erythromycin.
DR   DrugBank; DB00655; Estrone.
DR   DrugBank; DB00898; Ethanol.
DR   DrugBank; DB01466; Ethylmorphine.
DR   DrugBank; DB04841; Flunarizine.
DR   DrugBank; DB01544; Flunitrazepam.
DR   DrugBank; DB00472; Fluoxetine.
DR   DrugBank; DB01095; Fluvastatin.
DR   DrugBank; DB00176; Fluvoxamine.
DR   DrugBank; DB01320; Fosphenytoin.
DR   DrugBank; DB01159; Halothane.
DR   DrugBank; DB09054; Idelalisib.
DR   DrugBank; DB01181; Ifosfamide.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB00762; Irinotecan.
DR   DrugBank; DB00753; Isoflurane.
DR   DrugBank; DB01167; Itraconazole.
DR   DrugBank; DB09570; Ixazomib.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB06738; Ketobemidone.
DR   DrugBank; DB01026; Ketoconazole.
DR   DrugBank; DB00281; Lidocaine.
DR   DrugBank; DB00836; Loperamide.
DR   DrugBank; DB01601; Lopinavir.
DR   DrugBank; DB04871; Lorcaserin.
DR   DrugBank; DB09280; Lumacaftor.
DR   DrugBank; DB00772; Malathion.
DR   DrugBank; DB01043; Memantine.
DR   DrugBank; DB00532; Mephenytoin.
DR   DrugBank; DB04817; Metamizole.
DR   DrugBank; DB00333; Methadone.
DR   DrugBank; DB00763; Methimazole.
DR   DrugBank; DB01028; Methoxyflurane.
DR   DrugBank; DB00849; Methylphenobarbital.
DR   DrugBank; DB06710; Methyltestosterone.
DR   DrugBank; DB00379; Mexiletine.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB01110; Miconazole.
DR   DrugBank; DB00683; Midazolam.
DR   DrugBank; DB00745; Modafinil.
DR   DrugBank; DB00220; Nelfinavir.
DR   DrugBank; DB00238; Nevirapine.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB00184; Nicotine.
DR   DrugBank; DB01115; Nifedipine.
DR   DrugBank; DB04868; Nilotinib.
DR   DrugBank; DB00435; Nitric Oxide.
DR   DrugBank; DB09074; Olaparib.
DR   DrugBank; DB01173; Orphenadrine.
DR   DrugBank; DB04938; Ospemifene.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01074; Perhexiline.
DR   DrugBank; DB04930; Permethrin.
DR   DrugBank; DB00850; Perphenazine.
DR   DrugBank; DB00454; Pethidine.
DR   DrugBank; DB03575; Phencyclidine.
DR   DrugBank; DB01174; Phenobarbital.
DR   DrugBank; DB00252; Phenytoin.
DR   DrugBank; DB06209; Prasugrel.
DR   DrugBank; DB00794; Primidone.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB00908; Quinidine.
DR   DrugBank; DB00481; Raloxifene.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB01045; Rifampicin.
DR   DrugBank; DB08864; Rilpivirine.
DR   DrugBank; DB00503; Ritonavir.
DR   DrugBank; DB06176; Romidepsin.
DR   DrugBank; DB00296; Ropivacaine.
DR   DrugBank; DB00778; Roxithromycin.
DR   DrugBank; DB01037; Selegiline.
DR   DrugBank; DB01104; Sertraline.
DR   DrugBank; DB01236; Sevoflurane.
DR   DrugBank; DB00641; Simvastatin.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB06729; Sulfaphenazole.
DR   DrugBank; DB01138; Sulfinpyrazone.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB00231; Temazepam.
DR   DrugBank; DB00624; Testosterone.
DR   DrugBank; DB04572; Thiotepa.
DR   DrugBank; DB00208; Ticlopidine.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB00755; Tretinoin.
DR   DrugBank; DB00197; Troglitazone.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB00285; Venlafaxine.
DR   DrugBank; DB00661; Verapamil.
DR   DrugBank; DB09068; Vortioxetine.
DR   GuidetoPHARMACOLOGY; 1324; -.
DR   SwissLipids; SLP:000001346; -.
DR   iPTMnet; P20813; -.
DR   PhosphoSitePlus; P20813; -.
DR   BioMuta; CYP2B6; -.
DR   DMDM; 117205; -.
DR   PaxDb; P20813; -.
DR   PeptideAtlas; P20813; -.
DR   PRIDE; P20813; -.
DR   Ensembl; ENST00000324071; ENSP00000324648; ENSG00000197408. [P20813-1]
DR   GeneID; 1555; -.
DR   KEGG; hsa:1555; -.
DR   UCSC; uc002opr.2; human. [P20813-1]
DR   CTD; 1555; -.
DR   DisGeNET; 1555; -.
DR   GeneCards; CYP2B6; -.
DR   HGNC; HGNC:2615; CYP2B6.
DR   HPA; CAB033866; -.
DR   HPA; HPA048124; -.
DR   HPA; HPA062973; -.
DR   MalaCards; CYP2B6; -.
DR   MIM; 123930; gene.
DR   MIM; 614546; phenotype.
DR   neXtProt; NX_P20813; -.
DR   OpenTargets; ENSG00000197408; -.
DR   Orphanet; 240869; Efavirenz toxicity.
DR   PharmGKB; PA123; -.
DR   eggNOG; KOG0156; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00760000118775; -.
DR   HOGENOM; HOG000036992; -.
DR   HOVERGEN; HBG015789; -.
DR   InParanoid; P20813; -.
DR   KO; K17709; -.
DR   OMA; YREIEQV; -.
DR   OrthoDB; EOG091G0BT8; -.
DR   PhylomeDB; P20813; -.
DR   TreeFam; TF352043; -.
DR   BioCyc; MetaCyc:HS09587-MONOMER; -.
DR   BRENDA; 1.14.14.1; 2681.
DR   Reactome; R-HSA-211935; Fatty acids.
DR   Reactome; R-HSA-211981; Xenobiotics.
DR   Reactome; R-HSA-211999; CYP2E1 reactions.
DR   SABIO-RK; P20813; -.
DR   EvolutionaryTrace; P20813; -.
DR   GeneWiki; CYP2B6; -.
DR   GenomeRNAi; 1555; -.
DR   PRO; PR:P20813; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000197408; -.
DR   CleanEx; HS_CYP2B6; -.
DR   ExpressionAtlas; P20813; baseline and differential.
DR   Genevisible; P20813; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008392; F:arachidonic acid epoxygenase activity; IBA:GO_Central.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0004497; F:monooxygenase activity; IDA:BHF-UCL.
DR   GO; GO:0016712; F:oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; IEA:InterPro.
DR   GO; GO:0019825; F:oxygen binding; TAS:Reactome.
DR   GO; GO:0042180; P:cellular ketone metabolic process; IDA:BHF-UCL.
DR   GO; GO:0017144; P:drug metabolic process; IDA:BHF-UCL.
DR   GO; GO:0019373; P:epoxygenase P450 pathway; IBA:GO_Central.
DR   GO; GO:0042738; P:exogenous drug catabolic process; IDA:BHF-UCL.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:BHF-UCL.
DR   GO; GO:0008202; P:steroid metabolic process; IMP:BHF-UCL.
DR   GO; GO:0006805; P:xenobiotic metabolic process; IDA:UniProtKB.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   InterPro; IPR008068; Cyt_P450_E_grp-I_CYP2B-like.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR01685; EP450ICYP2B.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Endoplasmic reticulum; Heme; Iron; Membrane; Metal-binding; Microsome;
KW   Monooxygenase; NADP; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Reference proteome.
FT   CHAIN         1    491       Cytochrome P450 2B6.
FT                                /FTId=PRO_0000051683.
FT   METAL       436    436       Iron (heme axial ligand).
FT   MOD_RES     128    128       Phosphoserine; by PKA. {ECO:0000250}.
FT   VAR_SEQ       1     57       MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLG
FT                                NLLQMDRRGLLKSFLR -> MRCMLTNSHPWCGCDWQ (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055571.
FT   VAR_SEQ     162    321       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055572.
FT   VARIANT      21     21       Q -> L (in allele CYP2B6*10;
FT                                dbSNP:rs34883432).
FT                                {ECO:0000269|PubMed:15190123}.
FT                                /FTId=VAR_023563.
FT   VARIANT      22     22       R -> C (in allele CYP2B6*2 and allele
FT                                CYP2B6*10; dbSNP:rs8192709).
FT                                {ECO:0000269|PubMed:11470993,
FT                                ECO:0000269|PubMed:12642465,
FT                                ECO:0000269|PubMed:12721789,
FT                                ECO:0000269|PubMed:14551287,
FT                                ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016927.
FT   VARIANT      26     26       T -> S (in dbSNP:rs33973337).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_025206.
FT   VARIANT      28     28       D -> G (in dbSNP:rs33980385).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_025207.
FT   VARIANT      29     29       R -> P (in dbSNP:rs34284776).
FT                                /FTId=VAR_033819.
FT   VARIANT      29     29       R -> S (in dbSNP:rs33926104).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_025208.
FT   VARIANT      46     46       M -> V (in allele CYP2B6*11;
FT                                dbSNP:rs35303484).
FT                                {ECO:0000269|PubMed:15190123}.
FT                                /FTId=VAR_023564.
FT   VARIANT      99     99       G -> E (in allele CYP2B6*12;
FT                                dbSNP:rs36060847).
FT                                {ECO:0000269|PubMed:15190123}.
FT                                /FTId=VAR_023565.
FT   VARIANT     139    139       K -> E (in allele CYP2B6*8 and allele
FT                                CYP2B6*13; dbSNP:rs12721655).
FT                                {ECO:0000269|PubMed:14551287,
FT                                ECO:0000269|PubMed:15190123}.
FT                                /FTId=VAR_016948.
FT   VARIANT     140    140       R -> Q (in allele CYP2B6*14;
FT                                dbSNP:rs35773040).
FT                                {ECO:0000269|PubMed:15190123}.
FT                                /FTId=VAR_023566.
FT   VARIANT     167    167       P -> A (in dbSNP:rs3826711).
FT                                {ECO:0000269|PubMed:12721789,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_016924.
FT   VARIANT     172    172       Q -> H (in allele CYP2B6*6, allele
FT                                CYP2B6*7, allele CYP2B6*9 and allele
FT                                CYP2B6*13; dbSNP:rs3745274).
FT                                {ECO:0000269|PubMed:11243870,
FT                                ECO:0000269|PubMed:11470993,
FT                                ECO:0000269|PubMed:12642465,
FT                                ECO:0000269|PubMed:12721789,
FT                                ECO:0000269|PubMed:14551287,
FT                                ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|Ref.2, ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016925.
FT   VARIANT     259    259       S -> R (in allele CYP2B6*3;
FT                                dbSNP:rs45482602).
FT                                {ECO:0000269|PubMed:11470993,
FT                                ECO:0000269|PubMed:12642465}.
FT                                /FTId=VAR_016928.
FT   VARIANT     262    262       K -> R (in allele CYP2B6*4, allele
FT                                CYP2B6*6, allele CYP2B6*7 and allele
FT                                CYP2B6*13; slight decrease in activity;
FT                                dbSNP:rs2279343).
FT                                {ECO:0000269|PubMed:11470993,
FT                                ECO:0000269|PubMed:12642465,
FT                                ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|Ref.2, ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016926.
FT   VARIANT     289    289       N -> K (in dbSNP:rs34277950).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_025209.
FT   VARIANT     306    306       T -> S (in dbSNP:rs34698757).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_025210.
FT   VARIANT     328    328       I -> T (in dbSNP:rs28399499).
FT                                {ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_024716.
FT   VARIANT     391    391       I -> N (in allele CYP2B6*15;
FT                                dbSNP:rs35979566).
FT                                {ECO:0000269|PubMed:15190123}.
FT                                /FTId=VAR_023567.
FT   VARIANT     487    487       R -> C (in allele CYP2B6*5 and allele
FT                                CYP2B6*7; dbSNP:rs3211371).
FT                                {ECO:0000269|PubMed:11470993,
FT                                ECO:0000269|PubMed:12642465,
FT                                ECO:0000269|PubMed:12721789,
FT                                ECO:0000269|PubMed:14551287,
FT                                ECO:0000269|PubMed:15469410,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_016929.
FT   CONFLICT    146    146       I -> T (in Ref. 2; AAF13602).
FT                                {ECO:0000305}.
FT   CONFLICT    238    238       L -> P (in Ref. 2; AAF13602).
FT                                {ECO:0000305}.
FT   TURN         38     40       {ECO:0000244|PDB:3IBD}.
FT   HELIX        43     45       {ECO:0000244|PDB:3IBD}.
FT   HELIX        51     62       {ECO:0000244|PDB:3IBD}.
FT   STRAND       64     70       {ECO:0000244|PDB:3IBD}.
FT   STRAND       73     78       {ECO:0000244|PDB:3IBD}.
FT   HELIX        81     88       {ECO:0000244|PDB:3IBD}.
FT   TURN         89     93       {ECO:0000244|PDB:3IBD}.
FT   HELIX        94     96       {ECO:0000244|PDB:3IBD}.
FT   TURN        102    104       {ECO:0000244|PDB:3IBD}.
FT   HELIX       105    108       {ECO:0000244|PDB:3IBD}.
FT   TURN        113    115       {ECO:0000244|PDB:3IBD}.
FT   HELIX       118    134       {ECO:0000244|PDB:3IBD}.
FT   TURN        135    137       {ECO:0000244|PDB:3IBD}.
FT   HELIX       142    159       {ECO:0000244|PDB:3IBD}.
FT   TURN        160    162       {ECO:0000244|PDB:3IBD}.
FT   HELIX       168    184       {ECO:0000244|PDB:3IBD}.
FT   HELIX       193    209       {ECO:0000244|PDB:3IBD}.
FT   HELIX       212    224       {ECO:0000244|PDB:3IBD}.
FT   HELIX       230    254       {ECO:0000244|PDB:3IBD}.
FT   HELIX       264    274       {ECO:0000244|PDB:3IBD}.
FT   STRAND      275    278       {ECO:0000244|PDB:3IBD}.
FT   HELIX       283    285       {ECO:0000244|PDB:3IBD}.
FT   HELIX       288    316       {ECO:0000244|PDB:3IBD}.
FT   HELIX       318    331       {ECO:0000244|PDB:3IBD}.
FT   TURN        332    335       {ECO:0000244|PDB:3IBD}.
FT   HELIX       340    345       {ECO:0000244|PDB:3IBD}.
FT   HELIX       347    360       {ECO:0000244|PDB:3IBD}.
FT   STRAND      375    377       {ECO:0000244|PDB:3IBD}.
FT   STRAND      380    382       {ECO:0000244|PDB:3IBD}.
FT   STRAND      387    390       {ECO:0000244|PDB:3IBD}.
FT   HELIX       392    396       {ECO:0000244|PDB:3IBD}.
FT   TURN        399    401       {ECO:0000244|PDB:3IBD}.
FT   STRAND      402    404       {ECO:0000244|PDB:3IBD}.
FT   HELIX       410    413       {ECO:0000244|PDB:3IBD}.
FT   HELIX       432    434       {ECO:0000244|PDB:3IBD}.
FT   HELIX       439    456       {ECO:0000244|PDB:3IBD}.
FT   STRAND      457    460       {ECO:0000244|PDB:3IBD}.
FT   HELIX       465    467       {ECO:0000244|PDB:3IBD}.
FT   STRAND      473    480       {ECO:0000244|PDB:3IBD}.
FT   STRAND      486    490       {ECO:0000244|PDB:3IBD}.
SQ   SEQUENCE   491 AA;  56278 MW;  B9799164BE8FBF1D CRC64;
     MELSVLLFLA LLTGLLLLLV QRHPNTHDRL PPGPRPLPLL GNLLQMDRRG LLKSFLRFRE
     KYGDVFTVHL GPRPVVMLCG VEAIREALVD KAEAFSGRGK IAMVDPFFRG YGVIFANGNR
     WKVLRRFSVT TMRDFGMGKR SVEERIQEEA QCLIEELRKS KGALMDPTFL FQSITANIIC
     SIVFGKRFHY QDQEFLKMLN LFYQTFSLIS SVFGQLFELF SGFLKYFPGA HRQVYKNLQE
     INAYIGHSVE KHRETLDPSA PKDLIDTYLL HMEKEKSNAH SEFSHQNLNL NTLSLFFAGT
     ETTSTTLRYG FLLMLKYPHV AERVYREIEQ VIGPHRPPEL HDRAKMPYTE AVIYEIQRFS
     DLLPMGVPHI VTQHTSFRGY IIPKDTEVFL ILSTALHDPH YFEKPDAFNP DHFLDANGAL
     KKTEAFIPFS LGKRICLGEG IARAELFLFF TTILQNFSMA SPVAPEDIDL TPQECGVGKI
     PPTYQIRFLP R
//
